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Abstract: Protein aggregates or inclusion bodies are common hallmarks of age-related neurodegenerative disorders. Why 
these aggregates form remains unclear. Equally debated is whether they are toxic, protective, or simple by-products. In-
creasing evidence, however, supports the notion that in general aggregates confer toxicity and disturb neuronal function 
by hampering axonal transport, synaptic integrity, transcriptional regulation, and mitochondrial function. Thus, neurosci-
entists in search of effective treatments to slow neural loss during neurodegeneration have long been interested in finding 
new ways to clear inclusion bodies. Intriguingly, two studies using conditional neuron-specific gene ablations of auto-
phagy regulators in mice revealed that autophagy loss elicits inclusion body formation and a neurodegenerative cascade. 
Such studies indicate autophagy may be a built-in defense mechanism to clear the nervous system of inclusion bodies. 
This new finding has implications for our understanding of aging and neurodegeneration and the development of new 
therapies. First, we discuss the pathways underlying autophagy and its controversial role in cell death and survival regula-
tion. We then discuss the physiological role of autophagy in the aging process of the nervous system. In the final portion 
of this review, we discuss the therapeutic promise of inducing autophagy and the potential side effects of such treatments. 
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INTRODUCTION 
  Macroautophagy (here simply called autophagy) is a cel-
lular housekeeping process that degrades and recycles long-
lived proteins, large protein aggregates, and even entire or-
ganelles like mitochondria. The term autophagy is of Greek 
origin and translates literally as “the eating of oneself.” 
Autophagy is a dynamic process in which double membranes 
target and envelop cytoplasmic contents forming cytosolic 
vesicles, the autophagosomes (Fig. 1). Autophagosomes then 
fuse with lysosomal vacuoles that contain acidic hydrolases 
and other degradative enzymes. After the release of lysoso-
mal enzymes into the lumen of autophagosomes and the sub-
sequent degradation of the contents, free amino acids and 
breakdown products are released into the cytoplasm and re-
cycled for de novo biosynthesis.  
  Autophagy plays a physiological role in development, 
defense against pathogens, and adaptation to starvation. For 
example, amino acid release by autophagic degradation al-
lows newborns to maintain a stable energy level for survival 
after birth [21]. Thus, it should come as no surprise that stud-
ies link autophagy dysfunction and pathophysiological situa-
tions to diseases like cancer, myopathy, and neurodegenera-
tion. For example, a defect in autophagy causes Danon’s 
disease, which results in cardiomyopathy and mental retarda-
tion [27,38].  
MOLECULAR MECHANISM  
  Researchers are beginning to identify the molecular ma-
chinery responsible for autophagy in mammalian cells. Be-
cause autophagy is evolutionarily conserved, the discovery  
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of autophagy related genes (Atg) in yeast laid the foundation 
for the identification of their mammalian orthologs. Al-
though the picture remains incomplete, it is clear that a com-
bination of kinases, phosphatases, guanosine triphosphatases 
(GTPases), and ubiquitin-like proteins direct the autophagy 
process. 
  Autophagy consists of multiple steps (Fig. 2) executed by 
specialized molecules. During the initiation phase, induced 
by starvation or loss of insulin signaling, the kinase target of 
rapamycin (TOR, in yeast), a nutrient sensor and negative 
regulator of autophagy, becomes inactivated. Rapamycin is 
an effective inhibitor of TOR, as well as of its mammalian 
ortholog (mTOR), and promotes autophagy (Fig. 2). Upon 
deactivation of TOR, Atg13 becomes partially dephosphory-
lated and associates with Atg1, a serine/threonine kinase, 
which also binds to Atg17. Atg13 binding activates Atg1 and 
initiates autophagy [1,19]. 
  The second phase of the autophagy process involves the 
selection and targeting of the cargo into vesicles (Fig. 2). 
The cargo may consist of unfolded, ubiquitinated proteins 
too large for the proteasome to degrade, inclusion bodies, 
and injured mitochondria. The signals responsible for select-
ing the cargo for vesicle packaging are currently not clear. 
Equally unknown is the origin of the membranes that form 
the autosomal vesicle, but the endoplasmic reticulum (ER) is 
a candidate. At the molecular level, a class III phosphatidyl-
inositol 3-kinase (PtdIns3Kinase) complex, which includes 
Atg6 (called Beclin-1 in mammals), mediates the vesicle 
nucleation. 3-Methyladenine and Wortmannin can inhibit 
PtdIns3Kinases and prevent autophagy. 
  The third phase in autophagy involves vesicle expansion 
(Fig. 2), mediated by a series of steps that involve two ubi-
quitin-like conjugation systems (reviewed in [10,13]). In one 
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tial interaction with Atg7 and Atg10 (E1-like and E2-like 
ligase proteins respectively). In a second conjugation path-
way, Atg8, also called LC3 in mammals, undergoes a series 
of modifications. First, Atg 4 cleaves Atg8. Next, Atg7 acti-
vates Atg8, which then binds to Atg3. Finally, Atg8 is con-
jugated to phosphatidyl-ethanolamine (PE) [17]. 
  In the last step, the autophagosomes bind to and fuse with 
lysosomes for bulk degradation of their contents (Fig. 2). 
After degradation, free amino acids, nucleotides, fatty acids 
and breakdown products are released into the cytosol and 
recycled. 
AUTOPHAGY: CELL SURVIVAL OR CELL DEATH? 
  The exact role of autophagy in the nervous system is a 
matter of controversy. One view is that autophagy represents 
a compensatory, neuroprotective mechanism to clear toxic 
accumulation of misfolded proteins or defective mitochon-
dria, thereby slowing synaptic damage and increasing neu-
ronal survival. Along this line, studies have found that 
mTOR, an inhibitor of autophagy, becomes trapped in inclu-
sion bodies, promoting autophagy induction and clearance of 
toxic aggregates [30]. Additionally, rapamycin, an autophagy 
inducer, protects against the cytotoxic effects of different 
aggregate-prone proteins including polyglutamine containing 
proteins and mutant Tau [3]. 
  The opposing view derives from the observation that 
autophagosomes accumulate during a non-apoptotic form of 
cell death known as type II cell death [4]or autophagic cell 
death [12,41]. Although autophagosomes are present in both 
healthy and dying cells, they are frequently found at in-
creased levels in dying neurons. This observation leads to the 
notion that autophagy, or at least part of its machinery, might 
play a role in a cell death pathway [13]. Alternatively, pro-
ponents of the cell survival role of autophagy hypothesize 
that increased levels of autophagosomes found in dying or 
dead cells result from a failed survival attempt by the cell.  
  While the causal relationship between autophagy level 
and cell death is unclear, several studies have linked in-
creased rates of autophagy with different characteristics of 
cell death and degeneration. For example, studies have 
linked elevated levels of autophagy with increased amyloid 
precursor protein processing and amyloid  peptide genera-
tion associated with neurodegenerative diseases such as Alz-
heimer’s disease. In addition, researchers detected A pep-
tide production within autophagosomes [43]. Furthermore, 
Lurcher mice, whose mutant phenotype results from an ag-
gregate-prone protein, display autophagy associated with 
neuronal cell death [44]. 
  Further complicating the picture is the considerable over-
lap between the autophagic and apoptotic machinery. For 
Fig. (1). A. EM micrograph of an autophagosome. Note the typical double membrane wrap. B. EM micrograph of an autophagosome (arrow) 
next to a mitochondria (m). 
Fig. (2). Schematic model of the molecular events regulating autophagy. 
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example, Bcl-2 functions normally as an anti-apoptotic pro-
tein, but is anti-autophagic when it is ER-located and inhibits 
the protein Beclin-1 (Atg6) during autophagosome nuclea-
tion [9,16,28]. Another example of the autophagic and apop-
totic overlap involves embryonic fibroblasts. Embryonic 
fibroblasts treated with staurosporine undergo apoptosis. 
However, Bax/Bak knockout embryonic fibroblasts, which 
are resistant to apoptosis, undergo Beclin-1 dependent 
autophagic cell death in response to staurosporine [37]. 
  Atg5 is another link between autophagy and apoptosis. 
Atg5 expression induces autophagy linked to cell death by 
interacting with the Fas-associated death domain protein 
(FADD) [29]. In addition, proteolytic cleavage at the N-
terminus by the calcium dependant protease calpain targets 
Atg5 to mitochondria and subsequent binding to Bcl-xL me-
diates apoptotic cell death [40]. Expression of a truncated 
form (1-193) of Atg5 is sufficient to evoke apoptotic cell 
death in the absence of autophagy, indicating that the 
autophagic and apoptotic functions of Atg5 are independent 
of each other [40].  
  Ultimately, the cell survival and death functions of auto-
phagy might not be mutually exclusive and the balance be-
tween the two functions is likely critical in determining cel-
lular fate. For example, Atg5 overexpression in HeLa cells 
promotes both autophagy and cell death [29]. In addition, 
studies have shown that several autophagy genes, including 
Atg5, Atg8, and Beclin-1 in mammalian cells, are involved 
in autophagic cell death [29,37,41]. Stressed cells defective 
for the apoptotic pathway can undergo autophagic cell death, 
which anti-autophagy inhibitors such as 3-MA or Wortman-
nin can inhibit [41]. While the pan-caspase inhibitor, zVAD, 
blocks apoptosis, L929 cells die by autophagic cell death. 
Similarly, caspase-8 inhibition by RNAi in the presence of 
zVAD leads to enhanced autophagic cell death in the same 
cell line [41]. Finally, stressing apoptosis-deficient cells and 
denying autophagy induces necrotic cell death [18].  
  In sum, these observations led to the idea that autophagic 
cell death is a “fail-safe”, non-apoptotic cell death mecha-
nism [41]. An important implication of this cross-talk be-
tween cell death pathways is that the efficient blockage of 
cell death might require multiple inhibitors. 
  As we will discuss further in the following sections, 
autophagy is basically a survival mechanism. In some situa-
tions of cellular stress, however, cells can use parts of the 
autophagic machinery to generate cell death when apoptosis 
is inhibited or deficient. For example, it has been proposed 
that a critical step leading autophagy to a lethal outcome in 
L929 fibroblast cell lines is the degradation of catalase and 
the generation of reactive oxygen species (ROS) [42]. 
Caspase-8 inhibition in L929 cells activates the receptor in-
teracting protein (RIP), Jun kinase (JNK), and autophagy 
with selective catalase degradation and an accumulation of 
ROS, ultimately leading to cell death. In contrast, starvation 
induced autophagy in the same cell line does not lead to cata-
lase degradation, but instead promotes cell survival, indicat-
ing that different autophagic stimulations can lead to differ-
ent outcomes [42]. Finally, apoptosis and autophagic cell 
death are not mutually exclusive and may occur in the same 
cell at the same time [11,13,22].
ROLE OF AUTOPHAGY IN NEURONS 
  To understand the relationship between neuronal pathol-
ogy and autophagy, two independent groups generated con-
ditional Atg7 and Atg5 null mice, respectively [15,20]. Inter-
estingly, they found that neuron-specific Atg7 and Atg5 gene 
deletion in mice evokes progressive motor deficits, neurode-
generation, and inclusion body formation without corre-
sponding defects in proteasome function, indicating that 
autophagy loss alone sets off a neurodegenerative cascade. 
  Komatsu and his colleagues generated nervous system 
specific Atg7 conditional knockout mice. Atg7 is an E1-like 
enzyme required for autophagic vacuole formation. Brain-
specific Atg7 deficient mice exhibit reduced survival, up to 4 
weeks, and reduced body size. Most importantly, Atg7 
knockout mice reveal limb-clasping, abnormal reflexes, re-
duced movement coordination, and tremors indicating severe 
neurological defects. Neuronal loss was evident in the cere-
bral and cerebellar cortex. Specifically, pyramidal neurons 
were missing and signs of gliosis, which is a diagnostic indi-
cator of neurodegenerative events, appeared. As the Atg7 
knockout mice aged, there was an increase in ubiquitin-
containing inclusion bodies in their brains. Inclusion body 
formation was clearly due to a decrease in autophagy, be-
cause proteasome function remained normal. Similarly, Hara 
and colleagues reported a neurodegenerative phenotype for 
brain-specific Atg5 null mice [15]. These mice showed mo-
tor deficits, Purkinje cell loss, and inclusion bodies. Taken 
together, these findings suggest that autophagy plays a piv-
otal role in preventing inclusion body accumulation and neu-
rodegeneration, providing a neuroprotective effect. 
AUTOPHAGY AND AGING 
  Studies indicate that autophagy may increase longevity 
[2]. For example, caloric restriction, which has proven to 
increase life span in rodents, leads to dramatic induction of 
autophagy [26]. Genetic studies in the nematode, Caenor-
habditis elegans, further support the view that autophagy 
may slow aging. Stressors like limited food, high population 
density, heat, or exposure to the “dauer” hormone lead to 
reversible arrest in the third larval stage of the nematode 
[14]. This phase, the “dauer diapause”, is an adaptive stage 
that allows the organism to survive unfavorable and harsh 
environmental conditions. Rates of autophagy dramatically 
increase during dauer diapause [25]. However, ablation of 
the nematode ortholog of the autophagy gene beclin-1 abol-
ishes dauer survival and reduces life span. On the other hand, 
loss-of-function mutations in autophagy inhibitors such as 
Akt, TOR, and PtdIns3-kinase, all extend the life span of 
nematodes [14,39]. These observations are consistent with 
the view that inhibition of autophagy repressors may extend 
life span. 
  Another potential mechanism of autophagy anti-aging 
effects is the removal of damaged mitochondria, which leak 
free radicals. Studies have implicated reactive oxygen spe-
cies in accelerating aging [5]. Various cellular stress signals 
can lead to mitochondrial outer membrane permeability. In-
terestingly, mitochondria with increased mitochondrial mem-
brane permeability are selectively targeted into auto-
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might reduce oxidative damage. Autophagy of mitochondria 
can also have other clinical implications. For example, stud-
ies have linked lysosomal accumulation of subunit 9 of mito-
chondrial ATPase owing to incomplete degradation of mito-
chondria with neuronal ceroid lipofuscinosis and neurode-
generative disease [7]. 
  With age, deactivation of autophagy can occur, which in 
turn triggers age-related accumulation of inclusion bodies 
and consequent neurodegeneration. Investigations of post-
mortem brain tissue of AD and PD patients have revealed 
elevated autophagosome levels and decreased levels of Be-
clin-1 [36]. The aging pigment lipofuscin accumulates in 
lysosomes and the subsequent accumulation of indigestible 
lysosomal contents inhibits autophagy [5]. Additionally, re-
cent reports indicate that mutant Huntingtin (mtHtt) protein 
recruits Beclin-1, which impairs autophagy, setting off a 
vicious cycle of protein accumulation [36]. Similarly, dynein 
mutations cause ALS-like symptoms in mice. Dynein is a 
motor protein important for autophagosome-lysosome fu-
sion. Decreased dynein function results in autophagy and 
aggregate clearance defects [31]. Whether motor proteins 
and microtubule network defects play a role in limiting auto-
phagy induction in the aging nervous system remains a topic 
for future investigation. 
  To summarize, numerous studies point to the anti-aging 
properties of autophagy. Possible mechanisms of anti-aging 
activity include clearance of protein aggregates and the re-
moval of damaged mitochondria. Research indicating that 
decreased rates of autophagy with age lead to inclusion body 
accumulation and neurodegeneration further solidifies the 
view that autophagy is an important cell survival mechanism. 
THERAPEUTIC STRATEGIES 
  The knowledge that autophagy can clear toxic aggregates 
offers new opportunities for the development of drugs to 
combat progressive, age-related neurodegenerative disorders. 
Rapamycin, a drug currently used in humans to inhibit renal 
transplant rejection, is an early candidate for autophagy in-
duction therapy. Rapamycin alleviates neurotoxicity by 
clearing toxic, aggregate-prone proteins such as mtHtt or 
mutant Tau in animal models [3]. Additionally, it may offer 
added protective effects by removing injured mitochondria, 
which can leak ROS and cytochrome c. Researchers have 
also tested in clinical trials the ability of rapamycin to allevi-
ate gliomas in combination with anti-tumor drugs [8,33]. 
While physicians already use rapamycin clinically, its effect 
on the human nervous system remains unknown. Because 
mTOR signaling affects multiple pathways in addition to 
autophagy, rapamycin, although specific for mTOR, may 
have potential side effects. Among them is impaired wound 
healing and immune suppression. Nevertheless, prolonged 
use of rapamycin in cancer patients has not shown evidence 
of autophagy related side effects [34].  
  Although not yet demonstrated, long-term stimulation of 
autophagy might have additional risks. One concern is that 
elevated autophagy may lead to deleterious depletion of 
healthy mitochondria. Neurons are particularly sensitive to 
bio-energetic failure. In fact, mitochondrial dysfunction is an 
early event in the pathogenesis in many neurodegenerative 
disorders [24]. However, some respiratory complexes can be 
lowered 25 to 80% before brain mitochondria show evidence 
of lower rates of respiration or ATP production [6]. In addi-
tion, the lower steady state level of mitochondrial mass re-
sulting from enhanced autophagy in vitro does not result in 
complete mitochondria depletion, but rather decreases the 
amount by about 50% [32].  
  A potentially interesting approach to autophagy induction 
therapy is the use of a cocktail of autophagy inducers. For 
example, recent studies show that trehalose, a disaccharide 
sugar, enhances rates of autophagy independently of mTOR 
[35]. In addition, trehalose and rapamycin have an additive 
effect on the clearance of aggregate-prone proteins such as 
huntingtin or -synuclein mutant proteins. If we can estab-
lish that autophagy plays a beneficial role in acute brain inju-
ries such as stroke, short-term treatment with autophagy in-
ducers in combination with other neuroprotectants might 
prove useful in increasing neuronal recovery after brain in-
jury.  
FUTURE DIRECTIONS  
  Several fundamental questions remain. What is the cause 
of the selective vulnerability of certain neurons to autophagy 
loss? Reciprocally, what determines the tissue and cell speci-
ficity of autophagy induction? What are the molecular sen-
sors responsible for the initiation of autophagy? What are the 
molecular signals that target damaged organelles and aggre-
gates to autophagosomes? It will also be important to gain 
further insight into the cross-talk between autophagy and 
apoptosis to shed more light on the delicate balance between 
survival and cell death. Finally, we have yet to demonstrate 
the therapeutic benefits of autophagy, notably the alleviation 
or delay of neurodegeneration, in humans. However, data 
from animal models and in vitro systems justify prudent op-
timism. 
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